Protalix Biotherapeutics, Inc. (de) · AMEX:PLX
Protalix Biotherapeutics, Inc. (de) — Investor Presentation (February 2024)
14 slides from Protalix Biotherapeutics, Inc. (de)'s investor presentation, February 2024
Slide 1: Protalix Biotherapeutics Corporate Presentation
PROTALIX BIOTHERAPEUTICS CORPORATE PRESENTATION February 2024
Slide 2: Disclaimers
Disclaimers Third-Party Information This presentation also contains estimates and other data made by independent parties and Protalix relating to market size and growth and other data related to the industry in which Protalix operates. This data involves a number of assumptions and limitations, and
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. Forward-looking statements are neither histor
Slide 4: Investment Highlights
Investment Highlights A strong foundation to further expand Into the Rare Disease space Two Approved Drugs Clinical and Regulatory Expertise in Rare Elelyso® (alfataliglicerase in Brazil): FDA approved, commercially Genetic Space marketed drug for Gaucher disease. Strong clinical and regulatory expe
Slide 5: Product Pipeline
Product Pipeline Recombinant proteins designed to have potentially improved therapeutic profiles that target unmet medical needs and established pharmaceutical markets Discovery and Preclinical Phase I Phase II Phase III Marketing Application Elelyso® Gaucher Disease Approved in 23 markets (taligluc
Slide 6: Elelyso for Gaucher Disease
Elelyso® for Gaucher Disease First plant cell derived recombinant protein approved by the FDA Gaucher Disease Symptoms and Treatment • Rare autosomal recessive disorder: affects 1 in • Possible symptoms include enlarged liver and 40,000 people spleen, various bone disorders, easy bruising and • Gluc
Slide 7: Elfabrio for Fabry Disease
Elfabrio® for Fabry Disease Second plant cell derived recombinant protein approved by the FDA Fabry Disease Symptoms and Treatment • Progressive disease that can lead to renal failure, • Rare X-linked disease: affecting about one in every cardiomyopathy with potentially malignant cardiac 40,000 to 6
Slide 8: Fabry Disease Competitive Landscape
Fabry Disease Competitive Landscape ~$2B market (2022) expected to reach over $3.5B (2029), CAGR of 8.5% Product Name Fabrazyme® Replagal® Galafold® Elfabrio® Parent Company Mechanism ERT ERT Pharmacological chaperone ERT Approved for Adults and pediatric patients 2+ Adults (E.U. only) Accelerated a
Slide 9: Committed Commercial Partner Chiesi Farmaceutici S.p.A.
Committed Commercial Partner Global Partnership with Chiesi Farmaceutici S.p.A. • International research-focused • Committed global partner with pharmaceuticals and healthcare group with ~$3B in revenue experienced sales team • Operating in 30 countries with over 6,000 • Strategic focus on rare dise
Slide 10: Growing Focus on High Unmet Needs in Rare Disease Space
Growing Focus on High Unmet Needs in Rare Disease Space Focus on Rare Disease space Our Strategy: Focus on Rare Disease space Goal: Within 2 years, 4-6 discovery to PhII programs in the pipeline • Both genetic and non-genetic opportunities • Prioritize opportunities with LCM potential Rare Genetic •
Slide 11: Evolving Protalix: Addressing High Unmet Needs in the Rare Disease Space
Evolving Protalix: Addressing High Unmet Needs in the Rare Disease Space Leveraging track record of success into other rare diseases Strategy Striving for Continued Success in Rare Diseases (genetic and non-genetic) Track Record of Success in Rare Genetic Space Vision Next Steps Protalix Now Initial
Slide 12: Well Capitalized to Advance Protalix to Next Phase
Well Capitalized to Advance Protalix to Next Phase CASH REVENUE $41.0M (3Q’23) $55.0 in revenue (9 Months 2023) FINANCING NET BURN RATE Successfully completed a Note Projected: 0 to +$1.5 M/Q Exchange in 3Q’21 to effectively extend maturity from 2021 to 2024 and lower principal CASH RUNWAY DEBT Cash
Slide 13: Experienced Leadership Team
Experienced Leadership Team DROR BASHAN SHOSHI TESSLER, PH.D. EYAL RUBIN YARON NAOS YAEL HAYON, PH.D. President & CEO VP, Clinical Development SVP & CFO SVP of Operations VP of R&D & Regulatory Affairs Mr. Bashan has served as our Dr. Tessler joined Protalix in Mr. Rubin has served as our SVP Mr. Na
Slide 14: Accomplished Board of Directors
Accomplished Board of Directors ELIOT FORSTER, PH.D. DROR BASHAN POL F. BOUDES, M.D. GWEN A. MELINCOFF Chairman President & CEO, Director Director Director AHARON SCHWARTZ, PH.D. AMOS BAR SHALEV SHMUEL “MULI” BEN ZVI, PH.D. Director Director Director Corporate Presentation I February 2024 14
Protalix BioTherapeutics — Investor Presentation (February 2024) on 6ix